TVTX Earnings Travere Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.40 | 2026-05-04 | 10-Q |
| FY 2025 | 2025-12-31 | -0.29 | 2026-02-19 | 10-K |
| Q3 2025 | 2025-09-30 | -0.32 | 2025-10-30 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.61 | 2025-08-06 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.47 | 2026-05-04 | 10-Q |
| FY 2025 | 2024-12-31 | -4.08 | 2026-02-19 | 10-K |
| Q3 2025 | 2024-09-30 | -3.37 | 2025-10-30 | 10-Q |
| Q2 2025 | 2024-06-30 | -2.67 | 2025-08-06 | 10-Q |
| Q1 2025 | 2024-03-31 | -1.76 | 2025-05-01 | 10-Q |
| FY 2025 | 2023-12-31 | -1.50 | 2026-02-19 | 10-K |
| Q3 2024 | 2023-09-30 | -0.29 | 2024-10-31 | 10-Q |
| Q2 2024 | 2023-06-30 | -2.38 | 2024-08-01 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.27 | 2024-05-06 | 10-Q |
| FY 2024 | 2022-12-31 | -4.37 | 2025-02-21 | 10-K |
| FY 2023 | 2022-09-30 | -1.09 | 2024-02-20 | 10-K |
| FY 2023 | 2022-06-30 | -1.05 | 2024-02-20 | 10-K |
| FY 2023 | 2022-03-31 | -1.20 | 2024-02-20 | 10-K |
| FY 2023 | 2021-12-31 | -3.01 | 2024-02-20 | 10-K |
| Q3 2022 | 2021-09-30 | -2.17 | 2022-10-27 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.59 | 2022-08-04 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.